- Home
- ATYR vs NAUT Comparison
ATYR vs NAUT Comparison
Compare ATYR & NAUT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATYR
- NAUT
- Stock Information
- Founded
- ATYR 2005
- NAUT 2016
- Country
- ATYR United States
- NAUT United States
- Employees
- ATYR N/A
- NAUT N/A
- Industry
- ATYR Biotechnology: Biological Products (No Diagnostic Substances)
- NAUT Biotechnology: Laboratory Analytical Instruments
- Sector
- ATYR Health Care
- NAUT Industrials
- Exchange
- ATYR Nasdaq
- NAUT Nasdaq
- Market Cap
- ATYR 105.8M
- NAUT 104.7M
- IPO Year
- ATYR 2015
- NAUT N/A
- Fundamental
- Price
- ATYR $0.93
- NAUT $0.89
- Analyst Decision
- ATYR Buy
- NAUT Strong Sell
- Analyst Count
- ATYR 6
- NAUT 1
- Target Price
- ATYR $8.88
- NAUT $1.75
- AVG Volume (30 Days)
- ATYR 23.5M
- NAUT 372.5K
- Earning Date
- ATYR 11-06-2025
- NAUT 10-28-2025
- Dividend Yield
- ATYR N/A
- NAUT N/A
- EPS Growth
- ATYR N/A
- NAUT N/A
- EPS
- ATYR N/A
- NAUT N/A
- Revenue
- ATYR N/A
- NAUT N/A
- Revenue This Year
- ATYR $420.85
- NAUT N/A
- Revenue Next Year
- ATYR $1,919.44
- NAUT N/A
- P/E Ratio
- ATYR N/A
- NAUT N/A
- Revenue Growth
- ATYR N/A
- NAUT N/A
- 52 Week Low
- ATYR $0.68
- NAUT $0.62
- 52 Week High
- ATYR $7.29
- NAUT $3.03
- Technical
- Relative Strength Index (RSI)
- ATYR 27.94
- NAUT 63.86
- Support Level
- ATYR $0.68
- NAUT $0.84
- Resistance Level
- ATYR $0.86
- NAUT $0.92
- Average True Range (ATR)
- ATYR 0.08
- NAUT 0.06
- MACD
- ATYR 0.13
- NAUT 0.01
- Stochastic Oscillator
- ATYR 69.00
- NAUT 84.38
About ATYR aTyr Pharma Inc. Common Stock
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.
About NAUT Nautilus Biotechnolgy Inc.
Nautilus Biotechnology Inc is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the human proteome. The Company transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. Company's products includes: Proteome Analysis System, Reagent Kits, Software and analysis.